COMMUNIQUÉS West-GlobeNewswire

Allegro’s injectable osteoarthritis treatment generates positive safety results in preclinical studies
25/03/2025
Microparticle hydrogel shows clean systemic toxicity profile over 4 weeks and 13 weeks Treatment designed to restore shock-absorbing capacities of joints in osteoarthritis Allegro plans to start pivotal clinical trials [...]
CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program
25/03/2025
Press Release CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program CROSSJECT enhanced its collaboration with Eton Pharmaceuticals, Inc. (“Eton”) by [...]
CROSSJECT fait le point sur sa collaboration avec ETON PHARMACEUTICALS, Inc. et sur le programme ZENEO® Hydrocortisone dans le domaine de l'insuffisance surrénale
25/03/2025
Communiqué de presse CROSSJECT fait le point sur sa collaboration avec ETON PHARMACEUTICALS, Inc. et sur le programme ZENEO® Hydrocortisone dans le domaine de l'insuffisance surrénale CROSSJECT a renforcé sa [...]
Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan
25/03/2025
- Alumis to receive $40 million in upfront and near-term co-development payments, with potential for approximately $140 million in additional milestone and field option payments, plus tiered royalties on future sales - [...]
Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis
25/03/2025
Long-term disability and safety data from ALITHIOS open-label extension study on continuous treatment with Kesimpta vs. later switch from teriflunomide in relapsing multiple sclerosis (RMS) patients to be presented [...]
Valneva Announces Filing of 2024 Universal Registration Document and US Form 20-F
25/03/2025
Saint-Herblain (France), March 25, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the filing, on March 24, 2025, of its 2024 Universal Registration Document (URD) [...]
Valneva annonce le dépôt de son Document d’Enregistrement Universel 2024 et de son rapport annuel américain « Form 20-F »
25/03/2025
Saint-Herblain (France), 25 mars 2025 – Valneva SE (Nasdaq : VALN; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui le dépôt, le 24 mars 2025, de son Document d’enregistrement universel [...]
Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis
25/03/2025
Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis If approved, tolebrutinib would be the first and only brain-penetrant BTK inhibitor to both treat non- [...]
Communiqué de presse : Examen prioritaire accordé aux États-Unis à la soumission réglementaire relative au tolebrutinib pour le traitement de la sclérose en plaques
25/03/2025
Examen prioritaire accordé aux États-Unis à la soumission réglementaire relative au tolebrutinib pour le traitement de la sclérose en plaques S’il est approuvé, le tolebrutinib sera le premier et le seul inhibiteur de [...]
NMD Pharma presents preclinical data highlighting increased innervation of skeletal muscle with ClC-1 ion channel inhibition treatment in neuromuscular disease model
25/03/2025
Company presented clinical and preclinical data at the MDA Conference last week in Dallas, Texas Oral presentation included data from MuSK-MG rat model depicting increases in muscle function and improvements in the [...]
CORRECTION – Global Reach for Biotechs: Avance Clinical Secures MOUs with Four Premier Taiwanese Trial Sites
25/03/2025
TAIPEI, Taiwan and ADELAIDE, Australia, March 25, 2025 (GLOBE NEWSWIRE) -- Avance Clinical, a leading full-service global Contract Research Organization (CRO) specializing in high-quality, agile clinical biotech [...]
Nxera Pharma’s Partner Tempero Bio Initiates Phase 2 Trial with TMP-301 for Alcohol Use Disorder
25/03/2025
Tokyo, Japan and Cambridge, UK, 25 March 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner Tempero Bio, Inc. has initiated a Phase 2 trial of TMP-301, a potent, selective and [...]
SeaStar Medical to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025
24/03/2025
DENVER, March 24, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and [...]
Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights
24/03/2025
HUNTSVILLE, March 24, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug optimization technology, [...]
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
24/03/2025
BDC-4182 on track to start a clinical trial in gastric cancer in second quarter 2025 BDC-3042 Phase 1 clinical trial fully enrolled the highest dose cohort with no dose-limiting toxicities (DLTs), results will be [...]
OrthoPediatrics Corp. Named One the 2025 Best Places to Work in Indiana
24/03/2025
WARSAW, Ind., March 24, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS) , a company focused exclusively on advancing the field of pediatric orthopedics, today announced [...]
Option Care Health to Announce First Quarter 2025 Financial Results and Host Conference Call
24/03/2025
BANNOCKBURN, Ill., March 24, 2025 (GLOBE NEWSWIRE) -- Option Care Health Inc. (“Option Care Health”) (NASDAQ: OPCH), the nation’s largest independent provider of home and alternate site infusion services, today [...]
NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy
24/03/2025
First-in-human studies anticipated to begin in 2026 Engaged a top tier U.S. based contract manufacturer to ensure the highest standards of quality Currently in the advanced stages of formulation development for [...]
AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
24/03/2025
– Initiated analytical studies in Q4 2024 to prepare for a potential Biosimilar Biological Product Development (“BPD”) Type 2a meeting with the FDA in the second half of 2025 – – Pursuing a 351(k) regulatory pathway for [...]

Pages